ImPact Biotech will present updated interim data from its ongoing Phase 3 ENLIGHTED study evaluating Padeliporfin vascular targeted photodynamic (VTP) therapy for patients with low-grade upper tract urothelial cancer (UTUC). The data will be presented at the 16th European Multidisciplinary Congress on Urological Cancers (EMUC 2024), held November 7-10 in Lisbon, Portugal.
The poster presentation, titled "ENLIGHTED Phase 3 study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC)," will be presented by Gautier Marcq, M.D., M.Sc., on November 9, 2024. The presentation will be part of the EMUC24 Networking and Abstract Discussion Session.
Padeliporfin VTP represents a novel, minimally invasive drug-device combination designed for selective ablation of unresectable solid tumors. The therapy involves delivering non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Currently, Padeliporfin VTP is under evaluation in a pivotal Phase 3 trial for low-grade UTUC. Earlier-stage studies are either ongoing or planned for high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC).
ImPact Biotech has established collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center. The company has operations in the EU, Israel, and the US.
